Winning for Patients: Building Global Pharmaceutical Ecosystems & Delivering Breakthrough Medicines

[two_third last="no"]
Overview

June 23rd, 2017, Friday

Grand Ballroom

12:00 PM - 1:00 PM   Check-in

1:00 PM - 1:10 PM   Welcome Remarks

Bin Shi, PhD, President, SAPA‐GP; Head of External R&D/Licensing, Amgen Asia R&D Center

1:10 PM - 1:30 PM   Presidential Election Speeches                                                              

Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

 

Featured Presentation

1:30 PM - 2:00 PM

Grand Ballroom

1:30 PM - 2:00 PM   Delivering Cell and Gene Therapy: One Big Pharma’s Approach

Joseph Tarnowski, PhD, Senior Vice President, Cell and Gene Therapy Platforms, PTS, R&D, GlaxoSmithKline

 

Plenary Session I

2:15 PM - 3:45 PM

Grand Ballroom

Big Data and Artificial Intelligence: Emerging Paradigm to Accelerate Delivery of Transformational Therapies

 Session Chairs:

Yuchen Bai, PhD, Associate Scientific Director, Johnson & Johnson

Han Dai, PhD, Scientific Leader, GSK Fellow, GlaxoSmithKline

2:15 PM - 2:45 PM   The Role of Small and Big Data in Drug Discovery       

Gunaretnam (Guna) Rajagopal, PhD, Global Head of Computational Sciences within Discovery Sciences, Janssen R&D

2:45 PM - 3:15 PM   AI for Healthcare: Challenges and Opportunities. 

Sean Zhou,PhD, Senior Director, Head of Computer Aided Detection and Diagnosis, Siemens Healthineers

3:15 PM - 3:45 PM   Construction of Biomedical Big Data Platform in Shanghai Jiaotong University and the Children Hospital of Shanghai  

Gang(Gilbert) Feng,PhD, Executive Director of the Big Data Platform in Shanghai Jiaotong University-Yale University Joint Center for Biostatistics and Senior Consultant in the National Center for Blood Disease Translational Medicine at Shanghai

3:45 PM - 4:15 PM   Coffee Break        

 

Workshop I

4:00 PM – 5:15 PM

Centennial Ballroom II

Position Yourself for the Future – Power Plan for Success

Co-organized with ASCEND,

the largest non-profit Pan-Asian organization for business professionals in North America

Session Chairs:

Haifeng Cui,PhD, GSK Fellow, Chief Scientist, GlaxoSmithKline

Hao Sun,MS, Senior Scientist, GlaxoSmithKline

4:00 PM - 4:25 PM   Optimized Potential through Emotional Intelligence

Jen Groover,Human Potential & Business Expert, Author, International Speaker, Serial Entrepreneur, TV Personality, Inventor, Advisor, Advocate, Ascend

4:25 PM - 4:50 PM   One Person, but Many Faces of Leadership: Flexing Your Style as a Leader

Sue Crimmin, PhD, Vice President, Sample Management Tech, GlaxoSmithKline

4:50 PM - 5:15 PM   What’s next?

Carolyn Buser-Doepner, PhD, Vice President, Head of Discovery Partnerships with Academia (DPAc), GlaxoSmithKline

Job Fair

2:00 PM - 5:00 PM

Centennial Ballroom I

 Session Chairs:

Meizhen Feng, MS, Associate Principle Scientist, Merck & Co.

Yu Gao,MS, Research Associate, Teva Pharmaceuticals           

VIP Session A

Frazer

2:30 PM – 4:30 PM

CEO Forum: Innovative Drug R&D in China

 

Session Chairs:

Sean Zhang, MD, FCP, Site Head, Board Member, CMO, Hengrui Therapeutics

Xue Liang, PhD, Microbiome Scientist, Merck & Co. 

2:30 PM - 4:30 PM   Panel Discussion

Mingjiu Chen, PhD, President and CEO, BioSynergics Inc.

Xu Chen, EMBA, President, ExCell Bio

Jim (Jingjun) Huang, PhD, CEO, Ascendia Pharmaceuticals

Larry Huang,PhD, President, Ark Pharm, Inc.

Feng (Frank) Li, PhD, President, Alliance Pharma

Simon Li, MD, PhD, Chief Medical Officer, Vice President of CSPC Pharma

Jay Mei, MD, PhD, Founder and CEO, Antegene Corporation

Weikang Tao, PhD, CEO of R&D Centers, Vice President, Jiangsu Hengrui Medicine Co., Ltd

Jingang Wang, EMBA, CEO, CoSci Med-Tech Co. Ltd

Philip Wang, VP, Hisun Pharmaceutical Company

Jingyi Wang, MD, PhD, President of Kelun Pharmaceutical Research Institute

Junzhi(John) Yao, PhD, co-founder and CEO, TC Scientific

Dan Zhang, MD, MPH, MA, CEO, Fountain Medical Development Ltd

Ming-Qiang Zhang,PhD,Vice President of R&D, Head of Amgen Asia R&D Center

De-Min Zhu, PhD, President and CEO, Curelong Group

 

VIP Session B

2:15 PM - 5:00 PM

Centennial Ballroom III

US-China Public Private Partnership (PPP): Biopharma Development Zones, Technology Transfer and Government Affairs

Session Chairs:

James Fendrick, BS, President and CEO, Rockland Immunochemicals, Inc.

David Cragin, PhD, Associate Director, Merck & Co. 

2:15 PM - 2:45 PM   The City of Philadelphia’s China Initiatives and Our New Developments

Lauren Swartz, BA, SeniorDirector, International Business Investment, Department of Commerce, City of Philadelphia

2:45 PM - 3:15 PM   Development of SOTIO Immunotherapy: A Czech-China Story

Vladimír Hrůša, MBA, CEO of SotioMedical Research Co.

3:15 PM - 3:45 PM   Partnering with the National Cancer Institute: An American Success Story  

James Fendrick, BS, President and CEO, Rockland Immunochemicals, Inc.

3:45 PM - 4:15 PM   Coffee Break         

4:15 PM - 5:00 PM   Panel Discussion     

John Xu, MD, MBA, MS, Senior Vice President of Strategic Alliance, AbPro

Jim (Jingjun) Huang, PhD, CEO, Ascendia Pharmaceuticals

Lauren Swartz, BA, SeniorDirector, International Business Investment, Department of Commerce, City of Philadelphia

Vladimír Hrůša, MBA, CEO of SotioMedical Research Co.

VIP Session C

2:15 PM - 5:00 PM

Harverford

US-China CRO Landscape: Building Success with Strategic Alliances

Featuring Participants from US and China CROs and Industry Executives

 Session Chairs:

Li Cui, PhD, Investigator, GlaxoSmithKline

Weifeng Tang, MD, PhD, Director, AstraZeneca Pharmaceuticals 

2:15 PM - 2:40 PM   Connecting Science to Patients: Immuno-Oncology and Translational Oncology Platforms

Michelle Mack, MS, Director of Scientific Engagement, Crown Bioscience       

2:40 PM - 3:05 PM   CRO Landscape     

Henry Lu, PhD, Vice President and Head of Biology, WuXi AppTec 

3:05 PM - 3:30 PM   Clinical Development Outsourcing

Karen Chu, Pharma D,Corporate Vice President, Clinical Research Services,Parexel 

3:30 PM – 3:55 PM   Animal Models in Drug Discovery on Immunotherapy

Jun Wang, PhD, Vice President of Biology, Shanghai Medicilon, Inc. 

3:55 PM - 4:25 PM   Coffee Break 

4:25 PM - 5:00 PM   Panel Discussion     
Russell Dahl, PhD, Vice President, Global Business Development of Sundia

Mingjiu Chen, PhD, President and CEO, BioSynergics Inc.

Michelle Mack, MS, Director of Scientific Engagement, Crown Bioscience

Henry Lu, PhD, Vice President and Head of Biology, WuXi AppTec

Karen Chu,Pharma D,Corporate Vice President, Clinical Research Services,Parexel

Jun Wang, PhD, Vice President of Biology, Shanghai Medicilon, Inc.       

  

Networking

5:00 PM – 6:00 PM

  

Gala Dinner (Invitation Only)

6:00 PM – 9:30 PM

Grand Ballroom

Gala Host:

Jing Yang,PhD, Senior Principal Scientist, Bristol-Myers Squibb Company

Fang Shen, PhD, Principal Scientist, Janssen R&D 

6:00 PM – 6:05 PM   Special Remarks

Jijun Xing, PhD, Science and Technology Counselor, Chinese Consulate-General in New York 

6:05 PM – 6:35 PM   Guest Presentation

Dengxi Wang, MS, Deputy Secretary, CPC Xinxiang Municipal Committee and Mayor, Xinxiang Municipal People’s Government 

6:35 PM – 6:50 PM   Year-end Remarks

Bin Shi, PhD, President, SAPA‐GP; Head of External R&D/Licensing, Amgen Asia R&D Center 

 

6:50 PM – 6:55 PM   SAPA-GP 2017-2018 Plan and Presidential Election Result

Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline 

6:55 PM – 9:30 PM   Dinner and Networking

June 24th, 2017, Saturday

7:30 AM - 8:30 AM   Check-in and Continental Breakfast

8:30 AM - 8:35 AM  Welcome Remarks

Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline 

Featured Presentation

8:35 AM - 9:25 AM 

Grand Ballroom

8:35 AM - 9:00 AM   Kelun- Scientific Truth— Seeking, Ethics for Good

Jingyi Wang,MD, PhD, President of Kelun Pharmaceutical Research Institute 

9:00 AM – 9:25 AM   Situation and Present Policies of China’s Pharmaceutical Industry

Mingde Yu, Honorary President and Chair of Expert Committee, China Pharmaceutical Enterprise Association

Plenary Session II

9:30 AM - 10:30 AM 

Grand Ballroom

Innovative Medicines: Transforming Patient Care

 Session Chairs:

Yongchao Su, PhD, Associate Principal Scientist, Merck & Co.

Hanghang Zhang, PhD Candidate, Fels Institute of Cancer Research, Temple University 

9:30 AM - 10:00 AM   Together to Create a World Without Lung Cancer     

Li Mao, MD, Vice President and Head of the Johnson & Johnson China Lung Cancer Center 

10:00 AM - 10:30 AM   Engineering the Environment of the Gut to Treat Inflammatory Bowel Disease      

Gary D. Wu, MD, Ferdinand G. Weisbrod Professor in Gastroenterology, University of Pennsylvania, School of Medicine

10:30 AM - 10:45 AM   Coffee Break

 

Workshop II

10:45 AM - 12:15 PM 

Centennial Ballroom III

Regulatory and Market Access

Regulatory Pathways for Bringing Innovative Products to Markets: Addressing the Needs of Patients and Payers

Session Chairs:

Jim Wang, PhD, MBA, Head of Regulatory Affairs Strategy, Spark Therapeutics, Inc.

Yufeng Li, PhD, Clinical Scientist, GlaxoSmithKline 

10:45 AM - 11:15 AM   Orphan Product Development from First-in-Human Study to Regulatory Approval

Jim Wang, PhD, MBA, Head of Regulatory Affairs Strategy, Spark Therapeutics, Inc. 

11:15 AM - 11:45 AM   Development of Target Product Profile and Product Labeling

Paul Savidge, JD, MBA,Senior Regulatory Counsel, Spark Therapeutics, Inc. 

11:45 AM - 12:15 PM   Health Outcome Analysis for Payer Endorsement

Kim Gilchrist, MD, MBA,Senior Director, Value Evidence & Outcomes, GlaxoSmithKline  

Workshop III

10:45 AM - 12:15 PM 

Centennial Ballroom II

Perspectives of Biopharma R&D in China

 

Session chairs:

John Xu, MD, MBA, MS, Senior Vice President of Strategic Alliance, Abpro

Mengjie Si, PhD Candidate, School of Pharmacy, Temple University 

10:45 AM - 11:15 AM   Pharmaceutic R&D in China: Opportunities and Challenges and Keys to Managing a MNC R&D Center in China

Ming-Qiang Zhang,PhD, Vice President of R&D, Head of Amgen Asia R&D Center 

11:15 AM - 11:45 PM   Innovative Drug R& D in China: HengRui’s Experience and Perspectives

Weikang Tao, PhD, CEO of R&D Centers, Vice President, Jiangsu Hengrui Medicine Co., Ltd. 

VIP Session D

9:30 AM - 12:00 PM 

Haverford

Pharma/Healthcare Global Deal Dynamics Forum

Mergers and Acquisitions (M&A), Investment, and Business Development (BD)

 

Session Chairs:             

Patrick Deng, MBA, Finance Director, Johnson & Johnson

Michael Tang, JD, Tax Associate, EY 

9:30 AM - 10:00 AM   M&A and BD to Drive Exceptional Growth in Pharma/Generic Business

Jie Liu, MBA,Managing Director, New York Office, Torreya Partners 

10:00 AM - 10:30 AM   Deal Structure and Legal Considerations in Cross-border M&A and Investment Deals

Liang Xu, LLM,Partner, Hogan Lovells International 

10:30 AM - 11:00 AM   China Inbound M&A: Valuation Drivers & Tax Impacts

Min Fei, MS, Partner and China Tax Desk Leader, International Tax Services, EY

Yudan Zhang, CPA, MSA, Senior Manager, Transaction Advisory Services, EY 

11:00 AM - 11:30 AM   Coffee Break 

11:30 AM - 12:00 PM   The Cultural and Legal Challenges for Chinese Companies Doing Acquisition or Investment Deals in the US

Zhiping Liu, JD,Partner,Liu, Zheng, Chen & Hoffman LLP

Yong Chen, JD, PhD,Partner,Liu, Zheng, Chen & Hoffman LLP 

VIP Session E

9:30 AM – 12:00 PM, 1:30 PM - 3:30 PM

Centennial Ballroom I

SAPA-Hopkins Venture Forum

 

SAPA-Hopkins Venture Forum is a joint event proudly organized by Sino-American Pharmaceutical Professional Association-Great Philadelphia(SAPA-GP) and The Hopkins Club for Innovation and Entrepreneurship (The Hopkins Club). The forum brings together pharma and biotech leaders, emerging fast-growing companies, technology innovators, and members of the investment community with a focus on biohealth innovation and assets.

9:30 AM – 12:00 PM

Session Chair:

Ying(Charles) Wang, PhD, Scientific Director, GlaxoSmithKline

Zhen Lu, PhD, Application Scientist, Flarebio 

1:30 PM - 3:30 PM

Session Chair:

Han Dai, PhD, Scientific Leader, GSK Fellow, GlaxoSmithKline

Jiayi Zhang, PhD, Scientist, Paragon Bioservices 

Selected Portfolio Companies:

Harborgen Biotechnology, Renman Therapeutics LLC, Beta Biosciences, Inc., Center for Applied System Biology, Inc., TeraImmune LLC, B&H Biotechnologies LLC, DaVinci Healthx, Inc., Anson Diagnostics, Inc, Cosmos Insight LLC, LINKSciences

 

Lunch

11:45 AM - 12:45 PM

Lunch Session

12:15 PM - 1:15 PM

Aiming for Success: Biotechnology Entrepreneurship Boot Camp

Ardmore

Session chair: Xianhua Li, PhD Candidate, Villanova University, Department of Chemical Engineering

Speaker: Dennis Gross, PhD, CEO and Treasurer, Pennsylvania Drug Discovery Institute 

Six Key Successful Retirement Strategies

Paoli

Session chair: Yutai Li, PhD, Principal Scientist, Merck & Co.

Speaker: Carolyn Choh,MBA, Investment Adviser Representative with Financial Independence Planning, LLC.  

Harry Keller, CFP®, ChFC, CLU, MBA, CEO and Founder of Financial Independence Planning, LLC

Executive Development Programs: A Gateway to Leadership Excellence

Frazer

 Session chair: Hui Wang, PhD, Application Scientist, LINKSciences 

Speaker:Gaëlle Beltran-Grémaud, MBA, Senior Director, Aresty Institute of Executive Education, Wharton School, University of Pennsylvania

Michael Malefakis, MIA, Associate Vice Dean, Aresty Institute of Executive Education, Wharton School, University of Pennsylvania 

Latest Developments in PIV Litigation and New Opportunities for Obtaining Generic Exclusivity

 

Devon

 Session Chair: Dan Tian, PhD, University of the Sciences

Speaker: Stephen Yang, JD,Senior Associate, Alston & Bird LLP

Thomas J. Parker, JD, Partner, Alston & Bird LLP

Workshop IV

1:30 PM - 3:30 PM 

Centennial Ballroom III

Navigating through the Changing Regulatory Environment

CMC, Regulatory, Legal and Data Integrity Aspects of Bioequivalence studies

Session Chairs:

Lu Wang, PhD, Senior Scientist, Teva Pharmaceuticals

Chengwei Fang, PhD, Principal Investigator, DuPont Crop Protection 

1:30 PM - 2:00 PM   BA and BE Overview

Bangqian Xu,PhD, Chief Operating Officer, Oryza Pharmaceuticals Inc. 

2:00 PM - 2:30 PM   BE Study: Its Applications in Pharmaceutical Industry

Daniel Du, MD, PhD, Vice President of Clinical Services at Frontage Clinical Services, Inc. 

2:30 PM - 3:00 PM   Coffee Break 

3:00 PM - 3:30 PM   ANDA Filing, Hatch Waxman Litigation, and Post Grant Patent Challenge

Jason Luo, JD, PhD,Patent Attorney, Duane Morris LLP 

 

Workshop V

1:30 PM - 3:30 PM 

Centennial Ballroom II

Biosimilar Development: Strategies and Requirements

 

Session Chairs:

Yu Gao, MS, Research Associate, Teva pharmaceuticals

Yang Liu, PhD, Investigator, GlaxoSmithKline 

1:30 PM - 2:00 PM   Demonstration of Biosimilarity

Patrick Liu, MD, PhD, Vice President of Biologics R&D and Head of Global Bioassays and Technology, Teva Pharmaceuticals 

2:00 PM - 2:30 PM   Biosimilar Exclusivity and Interchangeability: A Legal Primer

Xin Tao, JD, Senior Associate, Hogan Lovells US LLP 

2:30 PM - 3:00 PM   Coffee Break

3:00 PM - 3:30 PM   Biosimilar Development in the US from Quality and Regulatory Perspective

Audrey Jia, PhD, Independent Consultant 

Workshop VI

1:30 PM - 3:30 PM 

Harverford

Current Trends and Future Directions of Clinical Trial Designs and Regulatory Science

In US and China

Session Chairs:

Shuang (Steve)Wu, PhD, MS Candidate in Biostatistics, Columbia University

Hao Wu, PhD, Technical Specialist, Howson & Howson, LLP 

1:30 PM - 2:00 PM   ICH 17 and Global Drug Development

William(Bill) Wang, PhD, Executive Director, Clinical Safety Statistics, Biostatistics and Research Decision Sciences(BARDS), Merck Research Laboratories 

2:00 PM - 2:30 PM   Safety Issues in Clinical Trials

Huabin Sun, MD, Medical Safety Officer/Director, Global Medical Safety, Janssen R&D 

2:30 PM - 3:00 PM   Coffee Break 

3:00 PM - 3:30 PM   In parallel Development of Clinical Programs in US and China 

Simon Li, MD, PhD, Chief Medical Officer, Vice President of CSPC Pharma 

 

3:30 PM - 3:35 PM   Closing Remarks                                                                                    Grand Ballroom

Zhenhua Wu, PhD, President-Elect, SAPA-GP; Associate Director, GlaxoSmithKline

 

3:35 PM – 3:45 PM   Raffle Drawing                                                                                       Grand Ballroom

Hui Wang, PhD, Application Scientist, LINKSciences

 

Program
Print Program [separator style_type="none" top_margin="10" bottom_margin="10" sep_color="" icon="" icon_circle="" icon_circle_color="" width="" alignment="center" class="" id=""]
Welcome, Day 1
Friday, June 23, 1:00 PM - 2:00 PM
1:30 PM - 2:00 PM
Plenary Session I
Friday, June 23, 2:15 PM - 4:15 PM

Big Data and Artificial Intelligence: Emerging Paradigm to Accelerate Delivery of Transformational Therapies

2:15 PM - 2:45 PM
Gunaretnam Rajagopal, PhD
Vice President, Global Head of Computational Sciences and Discovery Sciences, Johnson & Johnson
2:45 PM - 3:15 PM
Sean Zhou, PhD
Senior Director R&D, Head of Innovation and Software Development, Siemens Medical
3:15 PM - 3:45 PM
Gilbert Feng
Executive director of the Biomedical Big Data Platform in the National Center for Blood Disease Translational Medicine at Shanghai and the Center of Biotechnology Informatics in the National Center for Molecular Translational Medicine at Xi’an.
Dr. Gang (Gilbert) Feng is the executive director of the Biomedical Big Data Platform in the National Center for Blood Disease Translational Medicine at Shanghai and the Center of Biotechnology Informatics in the National Center for Molecular Translational Medicine at Xi’an. He is also the adjunct faculty member for Shanghai Jiaotong University-Yale Joint Center for Biostatistics, Northwestern University, Prevention Medicine, Health and BioMedicial Informatics(HBMI) Division and the 4th Military Medicine University. He got his BS in Biological Science and Biotechnology at Tsinghua University, MS in Biophysics and Computational Biology at University of Illinois at Urbana-Champaign, and PhD in Bioinformatics at University of Illinois at Chicago. Then he joined Northwestern University Feinberg School of Medicine as the senior biomedical informatics scientist and executive director of the Biomedical Informatics Research Collaboratory (BIRC), a part of the Center of Cancer and Nanotechnology Excellence (CCNE, supported by NCI), Robert H Lurie Comprehensive Cancer Center(supported by NCI), the Clinical and Translational Science Institute (NUCATs, supported by NIH) as well as a research track faculty member in the Department of Preventive Medicine. He had conducted and collaborated more than 100 high-dimensional clinical and research data analytical projects as well as published more than 20 peer review papers on high rank journals such as Nature Communications, PNAS, Bioinformatics, etc. He also developed two packages in Bioconductor, which is the largest international bioinformatics developing community. Both of them had been downloaded thousands of times. As the co-PI and key personal, he contributed a lot to a couple of projects funded by NIH, NCI and NSF. Due to his outstanding work, he was honored with caBIG Delivering Results Award by NCI. After he left from Northwestern University, he joined Appistry, a St. Louis based commercial cloud company focusing on biomedical applications and served NIH, FedEx and Lockheed-Martin, etc. He led a team to develop and integrate biomedical software on the commercial cloud computing platform.
Job Fair
Friday, June 23, 2:15 PM - 5:30 PM

Exhibition booths and limited interview rooms available. Please contact [email protected] for details.

VIP Session I
Friday, June 23, 2:15 PM - 5:00 PM

CEO Forum

VIP Session II
Friday, June 23, 2:15 PM - 5:00 PM

US-China Public Private Partnership (PPP): Biopharma Development Zones, Technology transfers and Government Affairs

Featuring participants from US and China government agencies and industrial executives

2:15 PM - 2:45 PM
2:45 PM - 3:15 PM
Kai Gu
Nanjing biotech and pharmaceutical Valley
3:15 PM - 3:45 PM
Ellen Zhang
General Manager, Guangzhou Guanhaobio

Ms. Ellen Zhang is the founder, partner and CEO of GuanHao Life & Health Incubator Co., LTD.  She established the company in 2013 in Guangzhou because she had a dream of helping entrepreneurs of start-up companies; she recognized a need for building a platform with characteristics of Chinese market.  Ellen designed a new business model to offer various services and guidance to start-up companies to transform their ideas into reality.   There are more than 70 companies in the Incubator, many of them are invested through her efforts, and some of them is ready for buy-out.

Ms. Zhang received an M.P.A degree from South China University of  Technology and an E.M.B.A degree from Sun Yat-Sen University.

Ellen was the Vice chairman of China Medical Industry Alliance, alliance vice chairman of Guangdong (Guangzhou) Precise Health Management Industry Technology Innovation, director of Guangzhou Incubators Association, vice chairman of Guangzhou Development District Postdoctoral Fellowship.

Ellen was the expert judge for several well-known Innovation Competition in China, such as 1000 Plan Start-up Contest, Sino-US Startup Competition in Life Science, Young Innovators & Entrepreneurs’Competition of Guangzhou and Overseas Innovation and Entrepreneurship Competition of Life and Health of Zhongshan, and mentor for sevel famous life and health incubators (Guanhao Incubator, Zhongda Innovation Valley and Guangdong Medical Valley)

3:45 PM - 4:30 PM
Jim Huang
Ascendia Pharma
John Xu
AbPro
Dr. John Xu got his medical degree from Shanghai Medical University (now Fudan medical college). He has more than 13 year early drug discovery research experience in BMS and Wyeth covering oncology and CNS areas. Dr. Xu also had a very successful business development experience for several large CRO companies such as WuXi AppTec, CrownBio and HD Biosciences.
During the seven years when he was responsible for global and US business development, he achieved the highest revenue for all the companies he had worked. He had built large network in biotech and pharmaceutical companies both in the US and China.
Currently, Dr. Xu serves as the Sr Vice President of strategic alliance for AbPro, a biotech company based in Boston. His responsibility includes building the strategic partnership to develop the therapeutic bi specific antibody with global bio tech and pharmaceutical companies.
Dr. Xu got his Master of Science and MBA degrees from US universities
VIP Session III
Friday, June 23, 2:15 PM - 5:00 PM

US-China CRO landscape: Building Success with Strategic Alliances

Featuring participants from US and China CROs and industrial executives

2:15 PM - 2:45 PM
Henry Lu
VP of biology Wuxi AppTec
2:45 PM - 3:15 PM
Michelle Mack
Director of Scientific Engagement at Crown Bioscience

Michelle Mack, Director of Scientific Engagement at Crown Bioscience brings 15 years of previous Oncology R & D experience from Pfizer Inc., where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included:  small-molecule inhibitors, antibody drug conjugates and nanoparticle based therapeutics.  Michelle’s scientific expertise span’s the preclinical and translational space for multiple solid and hematological tumor indications.  Throughout her professional career, Michelle has worked in Oncology, Immunology and Immuno-Oncology therapeutic areas.  She has several high-impact peer-reviewed publications and has led discussions at multiple scientific conferences.  Michelle obtained her undergraduate degree from Rochester Institute of Technology, Rochester, NY.  She then received her M.S. in microbiology and is currently completing her Ph.D. in molecular biology from Seton Hall University. 

Workshops I
Friday, June 23, 4:15 PM - 5:15 PM

Leadership Development

Position Yourself for the Future – Power Plan for Success

4:15 PM - 4:45 PM
Jen Groover
Ascend
Welcome, Day 2
Saturday, June 24, 8:00 AM - 9:00 AM
8:30 AM - 9:30 AM
Featured Presentation
Saturday, June 24, 9:00 AM - 9:30 AM
9:00 AM - 9:30 AM
Mingde Yu, PhD
President, Chinese Pharmaceutical Enterprises Association

Mr. Mingde Yu possesses decades of experiences in pharmaceutical manufacturing and commercialization management. Previously, he had been the Director of Chemical Industry Research Institute of Fuxin, Liaoning Province; Technology Chief and Factory Director of Fuxin Pharmaceutical Factory and Fuxin Chinese Medicine Factory; General Manager of Fuxin Pharmaceutical Corporation; Director of Fuxin Municipal Administration of Medicine; Deputy Director and Director of Provincial Administration of Medicine in Liaoning Province; Director of Finance Department and Market Circulation Department in the State Medicine Management Bureau; Director of Medicine Department and Deputy Director of the Economic Operations Bureau in State Economic and Trade Commission; Deputy Director of the Economic Operations Bureau in the National Development and Reform Commission.

Mr. Yu was invited to be a Research Scholar of the Medicine Research Center of Beijing University, Deputy Director of the Advisory Committee of Biopharmaceutical Experts sponsored by the National Development and Reform Commission, Honored Expert of the Innovative Drug Initiative Expert Committee sponsored by the Ministry of Science and Technology, Honored Expert of Medicine Circulation Industry Expert Committee sponsored by the Ministry of Commerce; Honored Expert of China’s 12th Five-Year Planning Expert Committee sponsored by the Ministry of Industry and Information Technology, Honored Expert of 9 Key Projects Assessment Committee sponsored by the Chinese Academy of Engineering. Mr. Yu is currently President of Chinese Pharmaceutical Enterprises Management Association, and President of China Pharmaceutical Entrepreneurs Association.

VIP Session IV
Saturday, June 24, 9:00 AM - 11:30 AM

Mergers and Acquisitions (M&A), Investment and Business Development (BD): pharma/Healthcare Global Deal Dynamics

9:00 AM - 9:30 AM
Jay Liu
Managing Director, Torreya Partners (Boutique life science investment bank in NYC and London)

Jie is a seasoned business development professional and has completed over 25 transactions in licensing, asset sales, co-promotion and M&A. He brings significant experiences and expertise in generics and specialty pharma.

Prior to joining Torreya, Jie was Vice President, Business Development & Licensing at Heritage Pharma, a subsidiary of Emcure Pharmaceuticals. Previously he was Senior Director, Global Business Development at Teva. Jie worked as Senior Director, Business Development at Auxilium and Director of Business Development at Cephalon.

Some notable transactions prior to joining Torreya includes Teva acquisition of Auspex for $3.5B in equity value; Teva’s acquisition of Labrys Biologics for up to $825M ($200M upfront); Teva’s collaboration with Microchips in implantable medical device for $35M in equity investment and technology access fee; Testim co-promote between Auxilium and GSK, Provigil co-promote between Cephalon and Takeda; Cephalon’s $350M stem cell deal with Mesoblast for $130M upfront and $220M equity stake; Cephalon’s acquisition of ChemGenex for $231M and Cephlaon’s acquisition of Salmedix for $160.

Jie is a native Mandarin speaker and received his undergraduate degree from Tianjin University in China. Jie is a licensed Speech Language Pathologist in the US. He holds an MBA in Healthcare from the Wharton School at University of Pennsylvania.

9:30 AM - 10:00 AM
Liang Xu
Partner, Hogan Lovells International (Renowned multinational law firm ranked #11 globally)

Working as a bilingual lawyer, Liang Xu has advised on many cross-border M&A transactions, both for Western corporations doing business in China, as well as Chinese enterprises (including SOEs and private companies) looking to expand and invest in global markets. His practice encompasses a variety of industries, including technology, automobile, manufacturing, energy, real estate, entertainment, educational and others. He has vast experience working with Chinese companies both as clients and as opponents, and is skilled in bringing the two sides of a dispute/transaction to a negotiated deal. Prior to joining Hogan Lovells in 2004, Liang was an in-house counsel with China Eastern Airlines Corporation Limited based in Shanghai.
Liang initially focused his practice on joint ventures, private equity and direct foreign investment matters for multinational clients. In recent years, with more and more Chinese companies going global, he has developed skills in advising and guiding Chinese companies through the Western style deal process, which is complicated for players from China who typically have insufficient global experience. Liang Xu is qualified in China and the New York State in the U.S., and is nominated as one of the Chambers Global leaders in the field of Corporate/M&A in China.

10:00 AM - 10:30 AM
Louis Liu
Partner, Liu, Zheng, Chen & Hoffman LLP

Mr. Liu focuses his practice in corporate transactions, concentrating in the formation of corporate entities, venture capital funding for start-up companies, mergers and acquisitions and general corporate governance matters. Mr. Liu has experience assisting clients in structuring and consummating over 100 corporate transactions totaling over $7 billion in value, including mergers, acquisitions, financings, restructurings and corporate reorganizations.

Representative Matters

The following is a selected sampling of recent matters where Mr. Liu acted as the lead counsel. It is provided for informational purposes only. Past success does not indicate the likelihood of success in any future matter:

  • Represented a hedge fund manager in establishing his own hedge fund under master-feeder structure with both U.S. and foreign investorsl;
  • Represented a bio-technology start-up companies in all of its corporate matters, including the corporate formation and the issuances of its Series A and Series B preferred stock to various accredited investors;
  • Represented a Massachusetts-based health care company in its acquisition of substantially all assets of a New Jersey-based health care service company;
  • Represented a Massachusetts-based health care company in its secured borrowing from a local bank;
  • Represented all of the shareholders of a Michigan-based fire alarm design and manufacturing company in the sale of the company to a strategic buyer from Europe;
  • Represented a China-based turbine manufacturer in all of its transactional matters in the United States, including acquisitions of wind farms and settlement of commercial disputes;
  • Represented a Chinese investor in the establishment and operations of a manufacturing plant in the United States;
  • Represented a private company in its acquisition of certain assets from a public traded company for approximately $70 million;
  • Represented a franchisee of a national restaurant chain to sell his franchise interests back to the franchisor for approximately $30 million;
  • Represented a Chinese state-owned enterprise in its sales of minority equity interests in a joint venture to its U.S. partner for approximately $200 million;
  • Represented a large Chinese Internet technology company in its acquisition of 30% of equity of a private Hong Kong company for approximately HK$50 million;
  • Represented a Virginia-based mining equipment company in the establishment of a joint venture in China;
  • Represented a prominent New York non-profit organization in its court-approved dissolution and transfer of its members and assets to a sister organization.

 Education

  • J.D., New York University School of Law
  • Baruch College, City University of New York (Jack Nash Honors Scholarship)
  • B.A. in Economics, Southwestern University of Finance and Economics (Chengdu, China)

Admissions

  • New York
  • Georgia
10:30 AM - 11:00 AM
Min Fei
China Tax Desk Leader, EY
11:00 AM - 11:30 AM
Yudan Zhang
Senior Manager, Transaction Advisory Services, EY
Plenary Session II
Saturday, June 24, 9:30 AM - 10:30 AM

Innovative Medicines: Transforming Patient Care

9:30 AM - 10:00 AM
Li Mao, PhD
Vice President, Head of Johnson & Johnson Lung Cancer Center
10:00 AM - 10:30 AM
Gary Wu, PhD
Professor in Gastroenterology, University of Pennsylvania School of Medicine
Workshops II
Saturday, June 24, 10:45 AM - 11:45 AM

Regulatory Pathways for Bringing Innovative Products to Market: Addressing the Needs of Patients and Payers

10:45 AM - 11:15 AM
Paul Savidge
Senior Regulatory Counsel, Spark Therapeutics, Inc.
11:15 AM - 11:45 AM
Jim Wang
Head of Regulatory Affairs Strategy, Spark Therapeutics, Inc.
11:45 AM - 12:15 PM
Kim Gilchrist
Senior Director, Value Evidence & Outcomes, GlaxoSmithKline.

Dr. Gilchrist joined GlaxoSmithKline supporting Infectious Disease area in the area, Value Evidence and Outcomes in 2011.  She is a Health Outcomes Research leader as well as Board certified Internal Medicine Practitioner, and Microbiologist with 20 years experience in clinical teaching and pharmaceutical drug development.  Her most recent infectious disease drug development focused on antibacterial, antiviral, and two HIV antiretroviral products (Dolutegravir, Efavirenz).   Prior to joining GSK, she led the US Health Outcomes group at AstraZeneca overseeing a full portfolio of products within respiratory, cardiovascular, oncology and infections disease.  Her early career focused on all facets of clinical development, particularly phase IIIB and IV,  Medical Affairs and Professional information,  Promotion and Medical review of advertising while at AstraZeneca and Dupont Pharmacueticals.    During her free time, she enjoys outdoor activities, sports, and dance in addition to time with her family

Workshops III
Saturday, June 24, 10:45 AM - 12:15 PM

Perspectives of Biopharma R&D in China

10:45 AM - 11:15 AM
Mingqiang Zhang, PhD
Vice President of R&D, Head of Amgen Asia R&D Center
11:15 AM - 11:45 AM
Weikang Tao
Henrui Therapeutics
11:45 AM - 12:15 PM
Jingyi Wang
President of the Research Institute, KELUN PHARMACEUTICAL Co., Ltd
Lunch Session
Saturday, June 24, 12:15 PM - 1:15 PM
12:15 PM - 1:15 PM
12:15 PM - 1:15 PM
Dennis M. Gross, MS, PhD
CEO & Treasurer, Pennsylvania Drug Discovery Institute

Dennis M. Gross, MS, PhD is the CEO, Treasurer and Professor of Pharmacology for the Pennsylvania Drug Discovery Institute and Professor of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute of the Hepatitis B Foundation. He is also Faculty in the Jefferson College of Biomedical Sciences and the Sidney Kimmel Medical College of Thomas Jefferson University (TJU). He recently retired from full‐time status at TJU where he was the Associate Dean for Program Development and Assessment and Director for the Professional Science Masters Programs. He was also Associate Professor of Pharmacology & Experimental Therapeutics in the Jefferson Medical College. Prior to this, he was at the Merck Research Labs for 29 years retiring in 2006 as Senior Director and Head of West Point Business Operations with overall responsibilities for capital planning and facilities in Pennsylvania, California and Massachusetts. He was also responsible for capital lab projects and operations oversight at Merck lab sites in Canada, Japan, Italy and the UK. In his career at Merck he held a number of positions ranging from bench scientist to head of computer resources, divisional data security administrator, manager of international strategic planning, M&A activities and liaison for basic research and clinical drug development in Japan.

During his tenure at Merck, he also served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University. He has worked with the Center for Strategic & International Studies in Washington, DC on policy issues relating to biological weapons of mass destruction. He received his BA (1969) and MS (1970) from California State University Northridge and his PhD (1974) from UCLA pursuing a postdoctoral fellowship at Tulane University School of Medicine. He has also participated in executive education programs at Wharton, MIT and the Tufts School of Law and received FEMA NIMS and ICS certification. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society, American Heart Association, Global STEM Alliance, History of Science Society, International Society for Pharmaceutical Engineering, and Sigma Xi.

12:15 PM - 1:15 PM
Carolyn Choh
Financial Independence Planning, LLC
Harry Keller
Financial Independence Planning, LLC
Workshops V
Saturday, June 24, 1:30 PM - 3:30 PM

Nutritional Supplements and Herbal Medicines: Unlock the global market potential

1:30 PM - 2:00 PM
Xin Tao
Associate, Hogan Lovells US LLP

With a working knowledge of regulatory requirements and a strong understanding of life science, Xin Tao works closely with clients in the food and drug industry to navigate the evolving federal and state regulatory environments and also communicate with agency officials and develop innovative regulatory strategies.
Xin's background in life science (biochemistry and molecular genetics) assists him in his science-based food and drug law practices. Xin advises clients on food and drug law with a particular focus on food ingredients, dietary supplements, and food and pharmaceutical packaging materials.

Xin has helped numerous food, dietary supplement, and pharmaceutical companies evaluate the need for marketing approval from the U.S. Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA). He also pursues clearance or pre-market approval when necessary and responds to FDA enforcement activities. Xin has advised numerous companies on issues relating to the advertising and promoting of products including the Federal Trade Commission (FTC)'s claim substantiation standards. Xin also has vast experience with FDA and USDA due diligence investigations for companies subject to takeover or merger activity. He assists with finalizing deals and identifies regulatory deficiencies. He is increasingly expanding his knowledge of California's Proposition 65 as it pertains to his clients.

Workshops VI
Saturday, June 24, 1:30 PM - 3:30 PM

Current Trends and Future Directions of Clinical Trial Designs and Regulatory science in China

1:30 PM - 2:00 PM
Jie Chen
Sr Global Group Head in Novartis China, head of biometrics & information sciences in AstraZeneca China and head of Biostatistics and statistical programming in Merck Serono China.
2:00 PM - 2:30 PM
Li Yan
GSK
2:30 PM - 3:00 PM
Simon Li
CSPC Pharmaceutical
Registration
[event post_id="8813"]#_BOOKINGFORM[/event]
Announcement
Sponsor
[/two_third] [one_third last="yes"]
Organizer
When
Start: 2017/06/23 (Friday) 01:00 PM
End: 2017/06/24 (Saturday) 05:00 PM
Where
Where

Sheraton Valley Forge Hotel
480 North Gulph Road King of Prussia, PA 19406

[/one_third]
2017-06-16T22:59:20+00:00